Entasis Therapeutics

73 articles about Entasis Therapeutics

• Entasis To Present Data On ETX2514 And Entasis’ Third Drug Candidate, ETX0282, At American Society of Microbiology Microbe 2017

  5/22/2017

• Entasis Appoints Mike Gutch As Chief Financial Officer And Chief Business Officer

  4/10/2017

• Entasis Announces Partnership With CARB-X To Support Development Of Oral, Gram-Negative Program

  3/31/2017

• Entasis Names Greg Norden, Former Senior Vice President And Chief Financial Officer Of Wyeth, To Its Board Of Directors

  11/29/2016

• Entasis To Present Data At IDWeek On ETX2514SUL, A Novel Drug Targeting Multidrug-Resistant Acinetobacter Baumannii Infections

  10/28/2016

• Entasis Announces Initiation Of Phase I Clinical Trial Of ETX2514

  10/26/2016

• Entasis Announces Positive Phase 2 Data Of ETX0914 For The Treatment Of Gonorrhea

  9/22/2016

• Entasis Presents Data Supporting The Potential Clinical Utility Of ETX2514, A Next-generation Beta-lactamase Inhibitor, At ASM Microbe 2016

  6/28/2016

• Entasis To Present Preclinical Data On ETX2514, A Next-Generation Beta-Lactamase Inhibitor, At ASM Microbe 2016

  6/15/2016

• Bay State Startup Entasis Banks $50 Million Series B

  4/5/2016

• Entasis Therapeutics Announces Appointments To Its Scientific And Clinical Advisory Board

  12/15/2015

• Entasis Therapeutics Appoints Robin David Isaacs As Chief Medical Officer

  7/15/2015

• AstraZeneca PLC's Antibiotics Alums Emerge at Biotech Spinout Entasis Therapeutics

  7/2/2015